GHRH analogue raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-05-18 and is reviewed periodically as new material appears.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
| Property | Value | Notes |
|---|---|---|
| Molecular weight (no linker) | ~3.37 kDa | Calculated from peptide sequence |
| Molecular weight (with linker) | ~3.65 kDa | Includes albumin-binding moiety |
| Appearance | White to off-white powder | Typically lyophilized |
| Solubility | Soluble in water | Also dissolves in aqueous buffers |
| Common synonyms | Modified GRF(1-29), DAC:GRF | Usage varies by source |
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
=== 2010-2013 === A book A Little War That Shook the World by Ronald Asmus was published in January 2010. One staff worker for Dick Cheney is quoted as expressing concern that American president George W. Bush had probably given Putin a "green light" to start hostilities against Georgia during the April 2008 meeting in Sochi. The book reported that French president Sarkozy said that he was ready to confront Russia on Georgia's NATO membership, but not German Chancellor Merkel. Germany's refusal to submit to the US proposal was a first time the US interests were neglected in the NATO and Putin used NATO's hesitation as an opportunity to wage the war against its neighbor. Asmus stated: "Many in the West tried to step back and pretend that the Russo-Georgian war was a local conflict they were not a party to." In October 2011, Dmitry Rogozin said in an interview with Echo of Moscow that Russia achieved that Ukraine and Georgia did not become NATO members and Russia gained respect. In 2011, Condoleezza Rice, former Secretary of State, published her memoirs where she wrote that she had told Saakashvili before the war not to respond to Russia because nobody would help him. She told The Weekly Standard that "But in no way were the Georgians at fault..." She said: "They were doing all kinds of things to try to provoke the Georgians. The shelling of Georgian cities by the South Ossetians, Russian allies, is clearly what started the war." Rice also talked about Russian hatred for Georgians.
In its Guidance for Industry "Data Integrity and Compliance With Drug CGMP" US-FDA states "it is the role of management with executive responsibility to create a quality culture where employees understand that data integrity is an organizational core value and employees are encouraged to identify and promptly report data integrity issues." Australia's Therapeutic Goods Administration has said that recent data integrity failures have raised questions about the role of quality culture in driving behaviors. In addition, non-governmental organizations such as the International Society for Pharmaceutical Engineering (ISPE) and the Parenteral Drug Association (PDA) have developed information and resources to help pharmaceutical companies better understand why quality culture is important and how to assess the current situation within a site or organization.
== Deaths == Deaths directly attributable to this form of heroin are difficult to confirm because coroner's offices frequently do not have a method to track cause of death to one specific form of a drug. Centralized reporting of cheese heroin deaths does not exist in Texas since each county has its own official to sign death certificates.
End-of-dose deterioration of function "On/off" oscillations Freezing during movement Dose failure (drug resistance) Dyskinesia at peak dose (levodopa-induced dyskinesia) Possible dopamine dysregulation: The long-term use of levodopa in Parkinson's disease has been linked to the so-called dopamine dysregulation syndrome. Rapidly decreasing the dose of levodopa can result in neuroleptic malignant syndrome. Clinicians try to avoid these side effects and adverse reactions by limiting levodopa doses as much as possible until absolutely necessary. Metabolites of dopamine, such as DOPAL, are known to be dopaminergic neurotoxins. The long term use of levodopa increases oxidative stress through monoamine oxidase led enzymatic degradation of synthesized dopamine causing neuronal damage and cytotoxicity. The oxidative stress is caused by the formation of reactive oxygen species (H2O2) during the monoamine oxidase led metabolism of dopamine. It is further perpetuated by the richness of Fe2+ ions in striatum via the Fenton reaction and intracellular autooxidation. The increased oxidation can potentially cause mutations in DNA due to the formation of 8-oxoguanine, which is capable of pairing with adenosine during mitosis. See also the catecholaldehyde hypothesis.
=== Semiconductors === Cadmium is an element in some semiconductor materials. Cadmium sulfide, cadmium selenide, and cadmium telluride are used in some photodetectors and solar cells. HgCdTe detectors are sensitive to mid-infrared light and used in some motion detectors.
Sources: en.wikipedia.org
=== Parasitic infections === Parasites are a diverse group of pathogens with significant health implications. Parasitic diseases can be transmitted through blood (e.g. malaria), contaminated water or food (e.g. Trichinella spiralis, Giardia duodenalis), penetration of skin or mucous membranes (e.g. Strongyloidiasis), and direct contact between hosts (e.g. Trichomonas vaginalis). Mast cells (MCs) tend to be located in strategic positions such as the subepithelial layers of skin, the respiratory system, the gastrointestinal tract, the genitourinary tract, and around blood vessels or nerves. Interactions between parasite and host are complex, involving parasite evasion strategies, host defense mechanisms, and continuous adaptation of both. Due to their strategic location in the host-environment interface MCs can provide rapid response capability. MCs can be activated in a parasite-specific manner through the detection of highly specialized molecular patterns related to pathogens (PAMPs) and microbes (MAMPs). The most characteristic feature of the immune system's response to parasite attack is the binding of immunoglobulin E (IgE) to the FcεRI receptor, which triggers MC degranulation and the release of mediators. These, in turn, trigger IgE-mediated type 2 responses, characterized by signaling from IL-4, IL-5, and IL-13. In responding to infection, mast cells orchestrate both first-line innate immune responses and adaptive immune processes in a variety of cell types.
== Chemical synthesis == A variety of synthetic approaches have progressively improved the efficiency and stereoselectivity of protolichesterinic acid synthesis while developing new methodologies for constructing similar lactone-containing natural products. The first total synthesis of dl-protolichesterinic acid was reported in 1958 by Eugene van Tamelen and Shirley Bach. Their synthesis involved a four-step route: conversion of methyl 2-hexadecenoate to methyl 3-tridecylglycidate, ring-opening with dimethyl malonate anion, formation of the lactonic diacid salt, and α-methylenation using formaldehyde and diethylamine. The synthetic material matched natural protolichesterinic acid by infrared spectroscopy and chemical transformations. In 1993, Murta, de Azevedo and Greene achieved the first synthesis of (-)-protolichesterinic acid, establishing its absolute stereochemistry as (2S,3R). Their approach employed a facially selective 2+2 cycloaddition of dichloroketene with an enantiopure O-alkyl enol ether as the key step, completing the synthesis in 11 steps with 17% overall yield. Mandal, Maiti and Roy reported a stereoselective synthesis in 1998 using radical cyclization of epoxides. Their method employed bis(cyclopentadienyl)titanium(III) chloride to effect radical cyclization, forming key tetrahydrofuran intermediates. The four-step sequence involved epoxide cyclization, protection, lactone formation, and Jones oxidation, achieving an 80% yield in the final step.
==== Urquía Carreño takes back his office ==== While he was not able to enter the building, Urquía Carreño still refused to step down, and called the election a coup d'etat, citing that the Grand Lodge of Cuba had not followed the proper procedures to impeach him. He said that because the Grand Lodge had not provided the Office of Associations at the Ministry of Justice with the official minutes of the session in which they ejected him from his office, their decision was not legally binding. He was subsequently endorsed by the Ministry of Justice. To prevent Kessel Linares from carrying out the office of Grand Master, the Ministry of Justice blocked the bank accounts of the Grand Lodge, prohibited them from carrying out certain activities, and suspended the Grand Lodge of Cuba from their Office of Associations, which is the office of Justice that oversees the Registry of Associations. Urquía Carreño told the Grand Lodge that if they continued in their current course of action, there would be "...more drastic and harmful measures..." that the Ministry of Justice could pursue. Over the next several months resumed the normal work of the office of Grand Master. Urquía Carreño also leveled accusations against all those Freemasons who had spoken to the press about the situation, that they had broken their solemn covenants and vows of secrecy to the fraternity. State television channels then sided with Urquía Carreño, urging the public to remain calm.
In September 2024, following the resolution of a prolonged pay dispute, it was announced that the term "junior doctor" within the NHS would be replaced with "resident doctor." This change was set to take effect on Wednesday, 18 September 2024.
Sources: en.wikipedia.org
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.
Early development used the albumin-binding form, and a shorter variant was later discussed under the same label. Because the two differ in half-life and handling, ambiguity arises whenever a source omits the variant designation.
The compound derives from that fragment but is not identical to it. The parent fragment lacks the stabilizing substitutions, so its degradation rate and duration of action differ noticeably.
Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.